AMENDMENTS TO THE CLAIMS

1. – 10. (Cancelled)

11. (Currently Amended) A process for the preparation of ~~a~~ **an aqueous** soluble inclusion compound comprising one or more active substances included in one or more host molecules, the active substance or substances not being very soluble in an aqueous medium, wherein it comprises the following successive steps:

a. bringing one or more active substances into contact with one or more host molecules,

b. carrying out a step of molecular diffusion by bringing a dense pressurized fluid into contact, in static mode, with the mixture obtained in step (a) in the presence of one or more diffusion agents,

c. **depressurizing and** recovering the active substance/host molecule molecular complex thus formed,

d. carrying out a step which consists in adding to and mixing with the active substance/host molecule molecular complex an agent for interaction with the complex **under atmospheric pressure in a semi-solid medium**,

e. recovering the **aqueous** soluble inclusion compound thus formed.

12. (Previously Presented) The process as claimed in claim 11, wherein the host molecule is chosen from the group consisting of saccharides or polysaccharides or their mixtures.

13. (Previously Presented) The process as claimed in claim 11, wherein the agent for interaction with the complex is an acid or a base.

14. (Previously Presented) The process as claimed in claim 13, wherein the agent for interaction with the complex is an amino acid, a carboxylic acid or aqueous ammonia.

15. (Previously Presented) The process as claimed in claim 11, wherein the dense pressurized fluid is carbon dioxide.

16. (Previously Presented) The process as claimed in claim 11, wherein the active substance is a pharmaceutical active principle, a cosmetic active principle or a nutraceutic active principle.

17. (Currently amended) The process as claimed in claim 16, wherein the active substance is chosen from the group consisting of **anilides** ~~anilide derivatives~~, **epipodophyllotoxins** ~~epipodophyllotoxin derivatives~~, minoxidil, piroxicam, valeric acid, octanoic acid, lauric acid, stearic acid, tiaprofenic acid, omeprazole, econazole, miconazole, ketoconazole, astemizole, cyclobenzaprine, nimesulide, ibuprofen, terfenadine, domperidone, naproxen and eflucimibe.

18. (Previously Presented) The process as claimed in claim 11, wherein the pressure of the dense fluid is between 0.5 Mpa and 50 MPa and the temperature between 0 and 200°C.

19.(Previously Presented) The process as claimed in claim 11, wherein the diffusion agent is chosen from the group consisting of alcohols, ketones, ethers, esters and water, with or without surfactant, and their mixtures.

20. (Currently Amended) The process as claimed in claim 11, wherein ~~stage~~ step (b) of molecular diffusion is carried out with stirring.

21. (Previously Presented) The process as claimed in claim 11, wherein the diffusion agent is added continuously or portionwise in an amount of between 1 and 50% by weight with respect to the total weight.

22. – 25. (Cancelled)

26. (Previously Presented) The process as claimed in claim 12, wherein the host molecule is selected from the group consisting of cyclodextrins and their mixture.